Table 1.
Distribution of clinical characteristics among two immune subtypes.
| Subtype 1 (N = 426) | Subtype 2 (N = 508) | p-value | |
|---|---|---|---|
| Dataset | 0.534 | ||
| GSE106977 | 56 (13.1%) | 63 (12.4%) | |
| GSE18864 | 20 (4.69%) | 18 (3.54%) | |
| GSE58812 | 51 (12.0%) | 56 (11.0%) | |
| GSE76124 | 82 (19.2%) | 116 (22.8%) | |
| GSE76250 | 72 (16.9%) | 93 (18.3%) | |
| GSE83937 | 55 (12.9%) | 76 (15.0%) | |
| GSE95700 | 27 (6.34%) | 30 (5.91%) | |
| TCGA-TNBC | 63 (14.8%) | 56 (11.0%) | |
| Age | 0.273 | ||
| (26,46) | 80 (28.3%) | 76 (22.8%) | |
| (46,55) | 76 (26.9%) | 84 (25.1%) | |
| (55,64) | 65 (23.0%) | 84 (25.1%) | |
| (64,90] | 62 (21.9%) | 90 (26.9%) | |
| Grade | <0.001 | ||
| Grade1 | 1 (0.66%) | 3 (1.60%) | |
| Grade2 | 25 (16.6%) | 64 (34.0%) | |
| Grade3 | 125 (82.8%) | 121 (64.4%) | |
| Primary tumor (T) | 0.011 | ||
| T1 | 27 (19.1%) | 37 (21.8%) | |
| T2 | 106 (75.2%) | 104 (61.2%) | |
| T3 | 6 (4.26%) | 18 (10.6%) | |
| T4 | 2 (1.42%) | 11 (6.47%) | |
| Regional lymph nodes (N) | 0.029 | ||
| N0 | 74 (61.7%) | 73 (50.0%) | |
| N1 | 35 (29.2%) | 40 (27.4%) | |
| N2 | 8 (6.67%) | 22 (15.1%) | |
| N3 | 3 (2.50%) | 11 (7.53%) | |
| Distant metastasis (M) | 0.624 | ||
| M0 | 115 (99.1%) | 127 (97.7%) | |
| M1 | 1 (0.86%) | 3 (2.31%) | |
| Stage | 0.320 | ||
| I | 16 (18.6%) | 12 (14.3%) | |
| II | 54 (62.8%) | 48 (57.1%) | |
| III | 14 (16.3%) | 23 (27.4%) | |
| IV | 2 (2.33%) | 1 (1.19%) |